BRPI0922345A2 - Composto, método para estabilizar uma célula isolada in vitro, para melhorar uma condição em um animal, e para manter e sobrevivência da célula tronco, e, população das células isoladas - Google Patents

Composto, método para estabilizar uma célula isolada in vitro, para melhorar uma condição em um animal, e para manter e sobrevivência da célula tronco, e, população das células isoladas

Info

Publication number: BRPI0922345A2
Authority: BR; Brazil
Prior art keywords: isolated cell; vitro; stabilizing; animal; maintaining
Prior art date: 2008-12-03

Application number

BRPI0922345-2A

Other languages

English (en)

Inventor

Yue Xu

Sheng Ding

Original Assignee

Scripps Research Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-03

Filing date

2009-12-03

Publication date

2015-08-11

2009-12-03 Application filed by Scripps Research Inst filed Critical Scripps Research Inst

2009-12-03 Priority to BR122021005861-0A priority Critical patent/BR122021005861B1/pt

2015-08-11 Publication of BRPI0922345A2 publication Critical patent/BRPI0922345A2/pt

2022-03-22 Publication of BRPI0922345B1 publication Critical patent/BRPI0922345B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Cell Biology (AREA)
General Engineering & Computer Science (AREA)
Developmental Biology & Embryology (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Hematology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)

BRPI0922345-2A 2008-12-03 2009-12-03 Composto, métodos in vitro para estabilizar uma célula animal isolada e para manter a sobrevivência da célula, e, composição BRPI0922345B1 (pt)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
BR122021005861-0A BR122021005861B1 (pt)	2008-12-03	2009-12-03	Composto, métodos para estabilizar uma célula animal isolada in vitro e para manter a sobrevivência da célula, e, composição

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20080808P	2008-12-03	2008-12-03
US61/200,808		2008-12-03
PCT/US2009/066554 WO2010065721A1 (en)	2008-12-03	2009-12-03	Stem cell cultures

Publications (2)

Publication Number	Publication Date
BRPI0922345A2 true BRPI0922345A2 (pt)	2015-08-11
BRPI0922345B1 BRPI0922345B1 (pt)	2022-03-22

Family

ID=42233609

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI0922345-2A BRPI0922345B1 (pt)	2008-12-03	2009-12-03	Composto, métodos in vitro para estabilizar uma célula animal isolada e para manter a sobrevivência da célula, e, composição
BR122021005861-0A BR122021005861B1 (pt)	2008-12-03	2009-12-03	Composto, métodos para estabilizar uma célula animal isolada in vitro e para manter a sobrevivência da célula, e, composição

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BR122021005861-0A BR122021005861B1 (pt)	2008-12-03	2009-12-03	Composto, métodos para estabilizar uma célula animal isolada in vitro e para manter a sobrevivência da célula, e, composição

Country Status (15)

Country	Link
US (7)	US8691573B2 (pt)
EP (7)	EP2789618B1 (pt)
JP (6)	JP5793795B2 (pt)
KR (1)	KR101551998B1 (pt)
CN (2)	CN105001196B (pt)
AU (7)	AU2009322346B2 (pt)
BR (2)	BRPI0922345B1 (pt)
CA (3)	CA3128456A1 (pt)
ES (5)	ES2971914T3 (pt)
HK (3)	HK1161590A1 (pt)
IL (2)	IL213205A (pt)
PT (1)	PT3623374T (pt)
SG (2)	SG171903A1 (pt)
WO (1)	WO2010065721A1 (pt)
ZA (2)	ZA201104019B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101551998B1 (ko) *	2008-12-03	2015-09-09	더 스크립스 리서치 인스티튜트	줄기 세포 배양
CN105861446B (zh)	2009-10-16	2021-10-01	斯克里普斯研究所	多能细胞的诱导
WO2011103196A1 (en)	2010-02-17	2011-08-25	Amgen Inc.	Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
EP2655601A4 (en)	2010-12-22	2014-09-10	Fate Therapeutics Inc	CELL CULTURAL PLATFORM FOR INDIVIDUAL CELL SIZING AND IMPROVED RESOLUTION OF IPSCS
CA2849244C (en) *	2011-09-22	2023-10-10	Karl Tryggvason	Cell culture substrate comprising a laminin and a cadherin
ES2779152T3 (es) *	2013-10-07	2020-08-13	Kadmon Corporation Llc	Derivados de (2-(5-isoindolin-2-il)pirimidin-4-il)-amina como inhibidores de Rho-quinasa para tratar enfermedades autoinmunes
WO2015134652A1 (en)	2014-03-04	2015-09-11	Bahram Valamehr	Improved reprogramming methods and cell culture platforms
US10023879B2 (en)	2014-06-04	2018-07-17	Fate Therapeutics, Inc.	Minimal volume reprogramming of mononuclear cells
CN105085489B (zh)	2014-11-05	2019-03-01	益方生物科技（上海）有限公司	嘧啶或吡啶类化合物、其制备方法和医药用途
CN114058582A (zh)	2015-01-26	2022-02-18	菲特治疗公司	用于诱导造血细胞分化的方法和组合物
CN117737124A (zh)	2015-10-16	2024-03-22	菲特治疗公司	用于诱导和维护基态多能性的平台
JP6928604B2 (ja)	2015-11-04	2021-09-01	フェイトセラピューティクス，インコーポレイテッド	万能性細胞のゲノム改変
EP3371301A4 (en)	2015-11-04	2019-06-26	Fate Therapeutics, Inc.	METHOD AND COMPOSITIONS FOR INDUCING THE DIFFERENTIATION OF HEMATOPOIETIC CELLS
EP3405568A4 (en)	2016-01-20	2019-12-04	Fate Therapeutics, Inc.	COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
WO2017156527A1 (en) *	2016-03-11	2017-09-14	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease
CN106632057B (zh) *	2016-08-23	2019-06-25	中国农业科学院兰州畜牧与兽药研究所	一种离子液体及利用其合成Thiazovivin的方法
JP7098615B2 (ja)	2016-12-05	2022-07-11	フェイトセラピューティクス，インコーポレイテッド	養子免疫療法における免疫細胞調節のための組成物および方法
US20230065740A1 (en)	2018-12-28	2023-03-02	Spv Therapeutics Inc.	Cyclin-dependent kinase inhibitors
JP7477983B2 (ja) *	2020-02-12	2024-05-02	株式会社カネカ	細胞凝集抑制剤
EP4271798A1 (en)	2020-12-30	2023-11-08	CRISPR Therapeutics AG	Compositions and methods for differentiating stem cells into nk cells
US20240262815A1 (en) *	2021-05-07	2024-08-08	Voronoi Inc.	Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient
WO2023233339A1 (en)	2022-06-01	2023-12-07	Crispr Therapeutics Ag	Compositions and methods for differentiating stem cells into nk cells
WO2023240248A2 (en)	2022-06-09	2023-12-14	Umoja Biopharma, Inc.	Compositions and methods for nk cell differentiation
AU2023314782A1 (en)	2022-07-27	2025-01-30	Umoja Biopharma, Inc.	Differentiation of stem cells in suspension culture

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5506337A (en)	1985-03-15	1996-04-09	Antivirals Inc.	Morpholino-subunit combinatorial library and method
EP0257275A3 (en) *	1986-07-28	1990-05-23	American Cyanamid Company	Cephalosporin and penicillin derivatives
US5010175A (en)	1988-05-02	1991-04-23	The Regents Of The University Of California	General method for producing and selecting peptides with specific properties
IE66205B1 (en)	1990-06-14	1995-12-13	Paul A Bartlett	Polypeptide analogs
US5650489A (en)	1990-07-02	1997-07-22	The Arizona Board Of Regents	Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
US5288514A (en)	1992-09-14	1994-02-22	The Regents Of The University Of California	Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5519134A (en)	1994-01-11	1996-05-21	Isis Pharmaceuticals, Inc.	Pyrrolidine-containing monomers and oligomers
US5593853A (en)	1994-02-09	1997-01-14	Martek Corporation	Generation and screening of synthetic drug libraries
US6117679A (en)	1994-02-17	2000-09-12	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5539083A (en)	1994-02-23	1996-07-23	Isis Pharmaceuticals, Inc.	Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en)	1994-06-22	1996-06-11	Affymax Technologies Nv	Methods for synthesizing diverse collections of pyrrolidine compounds
US5663046A (en)	1994-06-22	1997-09-02	Pharmacopeia, Inc.	Synthesis of combinatorial libraries
US5549974A (en)	1994-06-23	1996-08-27	Affymax Technologies Nv	Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5556752A (en)	1994-10-24	1996-09-17	Affymetrix, Inc.	Surface-bound, unimolecular, double-stranded DNA
US5958792A (en)	1995-06-07	1999-09-28	Chiron Corporation	Combinatorial libraries of substrate-bound cyclic organic compounds
US5569588A (en)	1995-08-09	1996-10-29	The Regents Of The University Of California	Methods for drug screening
US6185506B1 (en)	1996-01-26	2001-02-06	Tripos, Inc.	Method for selecting an optimally diverse library of small molecules based on validated molecular structural descriptors
WO1998017299A1 (en)	1996-10-18	1998-04-30	The Board Of Trustees Of The Leland Stanford Junior University	Isozyme-specific activators of protein kinase c, methods and compositions
SE511957C2 (sv)	1996-12-06	1999-12-20	Ericsson Telefon Ab L M	Broadcasting över ATM
US6399334B1 (en)	1997-09-24	2002-06-04	Invitrogen Corporation	Normalized nucleic acid libraries and methods of production thereof
EP0928790B1 (en) *	1998-01-02	2003-03-05	F. Hoffmann-La Roche Ag	Thiazole derivatives
EP2241541A1 (en)	1998-01-05	2010-10-20	Neogenesis, Inc.	Method for identifying a member of a mass-coded combinatorial library
US6841347B1 (en)	1998-02-05	2005-01-11	The General Hospital Corporation	In vivo construction of DNA libraries
US6541211B1 (en)	1998-05-20	2003-04-01	Selectide Corporation	Apparatus and method for synthesizing combinational libraries
AU7922900A (en) *	1999-10-27	2001-05-08	Novartis Ag	Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
MXPA02009185A (es)	2000-03-22	2003-05-23	Cellemetry Llc	Metodo y aparato para registrar la ubicacion electronica de un aparato movil de comunicaciones celulares.
WO2001090415A2 (en)	2000-05-20	2001-11-29	The Regents Of The University Of Michigan	Method of producing a dna library using positional amplification
EP1299381B1 (en) *	2000-06-28	2008-05-07	AstraZeneca AB	Substituted quinazoline derivatives and their use as inhibitors
JP3777158B2 (ja)	2000-11-10	2006-05-24	アミコージェン・インコーポレイテッド	一方向性の一本鎖ｄｎａ切片を用いた組換えｄｎａライブラリーの製造方法
US20020132823A1 (en) *	2001-01-17	2002-09-19	Jiahuai Han	Assay method
JP3857270B2 (ja)	2001-07-02	2006-12-13	アストラゼネカ・アクチエボラーグ	ケモカイン受容体活性のモジュレーターとして有用なピペリジン誘導体
HN2002000156A (es) *	2001-07-06	2003-11-27	Inc Agouron Pharmaceuticals	Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
EP1603905A1 (en) *	2003-02-10	2005-12-14	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
EP2543376A1 (en) *	2004-04-08	2013-01-09	Targegen, Inc.	Benzotriazine inhibitors of kinases
ATE499370T1 (de) *	2005-01-19	2011-03-15	Bristol Myers Squibb Co	2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen
EP1863794A2 (en) *	2005-03-16	2007-12-12	Targegen, Inc.	Pyrimidine compounds and methods of use
US20090069360A1 (en) *	2006-03-16	2009-03-12	David Bryant Batt	Organic Compounds
KR20090004976A (ko) *	2006-04-19	2009-01-12	아스테라스 세이야쿠 가부시키가이샤	아졸카르복사미드 유도체
TW200808325A (en) *	2006-07-06	2008-02-16	Astrazeneca Ab	Novel compounds
CN101563449A (zh) *	2006-09-22	2009-10-21	理化学研究所	干细胞培养基及干细胞培养方法
CA2668209A1 (en) *	2006-10-31	2008-05-08	Schering Corporation	Anilinopiperazine derivatives and methods of use thereof
US20080182328A1 (en) *	2006-12-19	2008-07-31	The Burnham Institute	Mammalian extraembryonic endoderm cells and methods of isolation
PL2368555T3 (pl)	2007-01-31	2017-02-28	Biosuccess Biotech Company	Kompozycje i sposoby stosowania estrów forbolu
US7838889B2 (en)	2007-08-10	2010-11-23	Eastman Kodak Company	Solid-state area illumination system
MX2010004499A (es) *	2007-10-24	2010-05-20	Astellas Pharma Inc	Compuesto de azolcarboxamida o sal de el.
NZ602832A (en) *	2008-07-14	2014-04-30	Gilead Sciences Inc	Fused heterocyclic hdac inhibitor compounds
WO2010012793A1 (en) *	2008-08-01	2010-02-04	Bayer Cropscience Sa	Fungicide aminothiazole derivatives
KR101551998B1 (ko)	2008-12-03	2015-09-09	더 스크립스 리서치 인스티튜트	줄기 세포 배양
US8004201B2 (en) *	2009-03-06	2011-08-23	Himax Analogic, Inc.	LED circuit
JO3421B1 (ar)	2011-06-20	2019-10-20	H Lundbeck As	طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية

2009
- 2009-12-03 KR KR1020117015337A patent/KR101551998B1/ko active IP Right Grant
- 2009-12-03 EP EP14175853.2A patent/EP2789618B1/en active Active
- 2009-12-03 ES ES21189950T patent/ES2971914T3/es active Active
- 2009-12-03 CA CA3128456A patent/CA3128456A1/en active Pending
- 2009-12-03 BR BRPI0922345-2A patent/BRPI0922345B1/pt active IP Right Grant
- 2009-12-03 SG SG2011040003A patent/SG171903A1/en unknown
- 2009-12-03 ES ES09831108.7T patent/ES2489040T3/es active Active
- 2009-12-03 EP EP19205703.2A patent/EP3623374B1/en active Active
- 2009-12-03 JP JP2011539689A patent/JP5793795B2/ja active Active
- 2009-12-03 PT PT192057032T patent/PT3623374T/pt unknown
- 2009-12-03 ES ES16174428T patent/ES2712074T3/es active Active
- 2009-12-03 BR BR122021005861-0A patent/BR122021005861B1/pt active IP Right Grant
- 2009-12-03 US US13/132,379 patent/US8691573B2/en active Active
- 2009-12-03 CN CN201510256027.1A patent/CN105001196B/zh active Active
- 2009-12-03 AU AU2009322346A patent/AU2009322346B2/en active Active
- 2009-12-03 ES ES19205703T patent/ES2898303T3/es active Active
- 2009-12-03 EP EP21189950.5A patent/EP3936508B1/en active Active
- 2009-12-03 EP EP16174428.9A patent/EP3103804B1/en active Active
- 2009-12-03 ES ES18196634T patent/ES2779001T3/es active Active
- 2009-12-03 EP EP23207671.1A patent/EP4296270A3/en active Pending
- 2009-12-03 WO PCT/US2009/066554 patent/WO2010065721A1/en active Application Filing
- 2009-12-03 SG SG2014000269A patent/SG196784A1/en unknown
- 2009-12-03 EP EP09831108.7A patent/EP2370445B1/en active Active
- 2009-12-03 EP EP18196634.2A patent/EP3441394B1/en active Active
- 2009-12-03 CA CA2995883A patent/CA2995883C/en active Active
- 2009-12-03 CA CA2745266A patent/CA2745266C/en active Active
- 2009-12-03 CN CN200980156028.1A patent/CN102307882B/zh active Active
2011
- 2011-05-29 IL IL213205A patent/IL213205A/en active IP Right Grant
- 2011-05-31 ZA ZA2011/04019A patent/ZA201104019B/en unknown
- 2011-06-01 US US13/150,933 patent/US8044201B2/en active Active
2012
- 2012-02-21 HK HK12101691.6A patent/HK1161590A1/xx unknown
- 2012-03-22 HK HK12102882.3A patent/HK1162488A1/xx unknown
- 2012-08-14 ZA ZA2012/06083A patent/ZA201206083B/en unknown
2013
- 2013-10-10 IL IL228818A patent/IL228818A/en active IP Right Grant
2014
- 2014-02-24 US US14/188,616 patent/US9340525B2/en active Active
2015
- 2015-07-22 JP JP2015144532A patent/JP6127092B2/ja active Active
- 2015-09-23 AU AU2015230747A patent/AU2015230747B2/en active Active
2016
- 2016-04-14 US US15/098,546 patent/US9896655B2/en active Active
- 2016-04-22 HK HK16104657.8A patent/HK1216883A1/zh unknown
2017
- 2017-02-01 AU AU2017200667A patent/AU2017200667B2/en active Active
- 2017-04-10 JP JP2017077236A patent/JP6476398B2/ja active Active
2018
- 2018-01-05 US US15/863,501 patent/US10351822B2/en active Active
- 2018-05-03 AU AU2018203091A patent/AU2018203091B2/en active Active
- 2018-12-26 JP JP2018242072A patent/JP6860544B2/ja active Active
2019
- 2019-06-04 US US16/431,643 patent/US10975352B2/en active Active
- 2019-07-30 AU AU2019210531A patent/AU2019210531B2/en active Active
2021
- 2021-03-08 US US17/195,385 patent/US20210403862A1/en active Pending
- 2021-03-25 JP JP2021050945A patent/JP7256218B2/ja active Active
- 2021-07-01 AU AU2021204635A patent/AU2021204635B2/en active Active
2023
- 2023-03-30 JP JP2023054562A patent/JP7621405B2/ja active Active
- 2023-10-17 AU AU2023251440A patent/AU2023251440A1/en active Pending

Also Published As

Publication number	Publication date
ES2779001T3 (es)	2020-08-13
AU2021204635A1 (en)	2021-07-29
US20180127712A1 (en)	2018-05-10
CN102307882A (zh)	2012-01-04
SG196784A1 (en)	2014-02-13
US10975352B2 (en)	2021-04-13
AU2015230747B2 (en)	2016-11-03
AU2017200667A1 (en)	2017-03-02
KR101551998B1 (ko)	2015-09-09
US20140273214A1 (en)	2014-09-18
AU2023251440A1 (en)	2023-11-09
EP4296270A2 (en)	2023-12-27
JP2021095419A (ja)	2021-06-24
EP3441394B1 (en)	2020-01-29
CN102307882B (zh)	2015-06-10
ZA201206083B (en)	2014-04-30
KR20110127119A (ko)	2011-11-24
AU2021204635B2 (en)	2023-07-20
AU2018203091A1 (en)	2018-05-17
EP3441394A1 (en)	2019-02-13
US20190352600A1 (en)	2019-11-21
US9896655B2 (en)	2018-02-20
EP2789618A1 (en)	2014-10-15
JP7256218B2 (ja)	2023-04-11
US20110224233A1 (en)	2011-09-15
CA3128456A1 (en)	2010-06-10
SG171903A1 (en)	2011-07-28
JP2017125061A (ja)	2017-07-20
EP3936508B1 (en)	2023-12-06
JP5793795B2 (ja)	2015-10-14
IL228818A (en)	2015-03-31
CA2995883C (en)	2023-01-24
JP7621405B2 (ja)	2025-01-24
EP2370445A1 (en)	2011-10-05
ES2712074T3 (es)	2019-05-09
EP3103804A1 (en)	2016-12-14
IL228818A0 (en)	2013-12-31
US8044201B2 (en)	2011-10-25
IL213205A (en)	2014-11-30
CN105001196B (zh)	2017-05-10
CA2995883A1 (en)	2010-06-10
BR122021005861B1 (pt)	2023-10-24
HK1162488A1 (en)	2012-08-31
ES2489040T3 (es)	2014-09-01
AU2017200667B2 (en)	2018-03-01
AU2018203091B2 (en)	2019-05-02
CN105001196A (zh)	2015-10-28
US20110294761A1 (en)	2011-12-01
IL213205A0 (en)	2011-07-31
CA2745266A1 (en)	2010-06-10
AU2009322346B2 (en)	2015-07-02
BRPI0922345B1 (pt)	2022-03-22
AU2019210531B2 (en)	2021-04-01
EP4296270A3 (en)	2024-01-03
CA2745266C (en)	2018-04-10
US9340525B2 (en)	2016-05-17
JP6860544B2 (ja)	2021-04-14
JP6476398B2 (ja)	2019-03-06
EP2370445B1 (en)	2014-07-23
EP2370445A4 (en)	2012-12-05
JP2012510526A (ja)	2012-05-10
PT3623374T (pt)	2021-11-17
US20210403862A1 (en)	2021-12-30
US10351822B2 (en)	2019-07-16
ES2898303T3 (es)	2022-03-07
EP3623374B1 (en)	2021-09-08
ES2971914T3 (es)	2024-06-10
AU2009322346A1 (en)	2011-06-30
AU2015230747A1 (en)	2015-10-29
JP2023073420A (ja)	2023-05-25
JP2016020347A (ja)	2016-02-04
ZA201104019B (en)	2012-11-28
EP3936508A1 (en)	2022-01-12
WO2010065721A1 (en)	2010-06-10
EP2789618B1 (en)	2016-07-27
AU2019210531A1 (en)	2019-08-15
EP3623374A1 (en)	2020-03-18
EP3103804B1 (en)	2019-01-30
JP6127092B2 (ja)	2017-05-10
JP2019043968A (ja)	2019-03-22
HK1216883A1 (zh)	2016-12-09
US8691573B2 (en)	2014-04-08
HK1161590A1 (en)	2012-07-27
US20160304833A1 (en)	2016-10-20

Publication	Publication Date	Title
BRPI0922345A2 (pt)	2015-08-11	Composto, método para estabilizar uma célula isolada in vitro, para melhorar uma condição em um animal, e para manter e sobrevivência da célula tronco, e, população das células isoladas
BRPI1009981A2 (pt)	2016-03-15	sistemas , métodos e composições para otimizar os enxertos enriquecidos de tecido e célula
BRPI0912386A2 (pt)	2016-07-26	composto, e, métodos para melhorar memória em um indivíduo e para tratar condições relacionadas a uma quinase
BRPI0908092A2 (pt)	2015-08-25	Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante
BRPI0814299A2 (pt)	2015-02-03	Preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida
BRPI0916015A2 (pt)	2015-11-03	"palmilha, método para fabricação de uma palmilha e calçado"
BRPI0912384A2 (pt)	2015-10-13	composição, e, método para preparar uma composição
BRPI0914208A2 (pt)	2015-11-03	célula de eletrólise, e, método
BRPI0904322A2 (pt)	2015-06-30	Célula solar sensibilizada por corante, e, método para produção de uma célula solar sensibilizada por corante.
BRPI0807756A2 (pt)	2014-06-17	Método para produzir um l-aminoácido.
BRPI0916689A2 (pt)	2015-11-17	composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
BRPI0924664A2 (pt)	2016-01-26	eletrodo ,e ,método para construir um eletrodo.
IT1395716B1 (it)	2012-10-19	Cuscinetto, meccanismo di fissaggio e metodo per fissare almeno un pattino.
PT1917029E (pt)	2013-03-13	Um método de tratamento de células cancerígenas para criar uma célula cancerígena modificada que provoca uma resposta imunogénica
BRPI1013430A2 (pt)	2015-09-01	Células acetogênicas, acetona e método para a fabricação da mesma
BRPI0716048A2 (pt)	2013-09-17	bateria e mÉtodo para fabricaÇço de um catodo para uma bateria.
BRPI1011264A2 (pt)	2016-03-22	método para fabricar uma bateria de eletrólito sólido, e, bateria de eletrólito sólido.
BRPI0916787A2 (pt)	2018-03-13	artigo, e, método para fabricar um artigo
BRPI0717451A2 (pt)	2013-12-24	Anodo para eletrólise
BRPI0918661A2 (pt)	2015-12-01	hélice, vaso, e, método para montagem de uma hélice
BRPI0909552A2 (pt)	2015-09-22	método, conjunto e kit para fixação de um artigo em uma superficie de suporte e artigo.
BRPI1013889A2 (pt)	2015-08-25	Célula de levedura, e, método para gerar uma célula de levedura.
BR112012002771A2 (pt)	2017-02-21	armação para uma célula galvânica, célula, galvânica, método para produzir uma célula galvânica e método para montar um bloco
BRPI0915289A2 (pt)	2016-02-16	inserto para solas, sola, e, calçado.
BRPI0913136A2 (pt)	2016-01-05	método para produzir uma peça e peça.

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2020-06-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-11-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-12-08	B15K	Others concerning applications: alteration of classification	Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 513/02 Ipc: C07D 513/02 (2006.01), C07D 417/12 (2006.01), C07D
2020-12-29	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-04-27	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2021-09-08	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2022-01-11	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-03-22	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/12/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.